Biopharma Musings | Genetic Medicine & Rare Disease | Buyside Turned Operator | Not Investment Advice | DYODD
Joined December 2020
- Tweets 2,147
- Following 771
- Followers 13,559
- Likes 3,347
372 Photos and videos
Professor Oak retweeted
May 29
Lorlatinib wears the crown for first-line treatment of advanced ALK lung cancer, which typically affects younger, non-smokers:
3
19
139
42,244
Professor Oak retweeted
May 21
1/8 🚨 New preprint from the @SternbergLab & Jinek labs! CRISPR-associated transposases (CASTs) insert large DNA cargoes at precise genomic locations — no double-strand breaks needed.
6
63
265
25,420
May 20
Expect more of this
Interesting implications not only for China but also for domestic fast-followers... how can you have confidence in your head-to-head functional assay if you don't know you made the right comparator?
12
20
108
30,897
May 19
So we’re all just ignoring the hundreds of millions of dollars worth of biobucks royalties China rights NewCo equity?
May 18
A US-based biotech VC told @damiangarde: "you can spend $10 million on a best-in-class drug from China, or you can hire 25 people in the US & pay them some $40 million over 3 years to get to the exact same point. In general, going with China works out to a roughly 50% cost savings, he said, meaning the same monetary investment can fund double the work."
4
3
29
14,000
Professor Oak retweeted
May 13
Autonomous science promises to augment scientific discovery, but current LLMs tend to mode collapse into low-diversity generations. We introduce “Unlocking LLM Creativity in Science through Analogical Reasoning”, which uses analogies to generate better candidate solutions! [1/N]
5
15
71
7,569
May 12
Due to popular demand, after a brief hiatus, Oak’s ASGCT abstract dump is back - now it’s 5th installment, better than ever
Posting later than I’d hoped - still shaking off the rust - but the show must go on; & what’s better than starting ASGCT Day 2 with the thread you needed 2 weeks ago?
(1/21)
4
4
90
13,670
May 12
Letting AI carry us on over to “C”…
Inaugural data release from Lila, the company “building scientific superintelligence to solve humankind’s greatest challenges,” is... an in vivo CD20 CAR-T! (#3251)
Even the road to a new age of boundless discovery has to start somewhere, I guess (18/21)
1
1,835
May 12
Speaking of, ENTIRELY too much in vivo CAR-T this year. Hundreds of abstracts, of which just a few piqued my interest
Kelonia $LLY BCMA-LVV non-clin data de-risk key specificity Q’s for LVV, as profile - in terms of both transduction & expression - looks v clean (#2264)
$OPK CD3xCD28-targeted LNP to deliver CD19 CAR mRNA, an interesting strategy to enhance specificity & T cell activation (#338)
$SNY tLNP-CD19 CAR (#343) reminded me Tidal M&A was in 2021! 3-5 yrs before all of pharma aped in, yet hopelessly behind today… (19/21)
4
1,912